Role of the glucagon-like-peptide-1 receptor in the control of energy balance

Physiology and Behavior

Volumn 100, Issue 5, 2010, Pages 503-510

  Hayes, Matthew R ^a   De Jonghe, Bart C ^a   Kanoski, Scott E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ANTIOBESITY AGENT; EXENDIN 4; EXENDIN 9; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; LEPTIN; LIRAGLUTIDE; PEPTIDE YY [3-36]; UNCLASSIFIED DRUG;

ARTICLE; BRAIN FUNCTION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; ENERGY BALANCE; FOOD INTAKE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MORBID OBESITY; NEUROENDOCRINOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN TARGETING; RHOMBENCEPHALON; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS; STOMACH BYPASS;

ANIMALS; DRUG ADMINISTRATION ROUTES; EATING; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 77953724336     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2010.02.029     Document Type: Article

References (127)

1. Creutzfeldt W. The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 2001, 109(Suppl 2):S288-S303.
2. Mojsov S., Kopczynski M.G., Habener J.F. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem 1990, 265:8001-8008.
3. Kokrashvili Z., Mosinger B., Margolskee R.F. Taste signaling elements expressed in gut enteroendocrine cells regulate nutrient-responsive secretion of gut hormones. Am J Clin Nutr 2009, 90:822S-825S.
4. Larsen P.J., Tang-Christensen M., Holst J.J., Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997, 77:257-270.
5. Goke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995, 7:2294-2300.
6. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999, 403:261-280.
7. Hayes M.R., Skibicka K.P., Grill H.J. Caudal brainstem processing is sufficient for behavioral, sympathetic and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008.
8. Kinzig K.P., D'Alessio D.A., Seeley R.J. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 2002, 22:10470-10476.
9. Schick R.R., Zimmermann J.P., vorm Walde T., Schusdziarra V. Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Regul Integr Comp Physiol 2003, 284:R1427-R1435.
10. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., Parkinson J.R., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005, 1044:127-131.
11. Chelikani P.K., Haver A.C., Reidelberger R.D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1695-R1706.
12. Imeryuz N., Yegen B.C., Bozkurt A., Coskun T., Villanueva-Penacarrillo M.L., Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997, 273:G920-G927.
13. Sandoval D.A., Bagnol D., Woods S.C., D'Alessio D.A., Seeley R.J. Arcuate GLP-1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008.
14. Knauf C., Cani P.D., Perrin C., Iglesias M.A., Maury J.F., Bernard E., et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005, 115:3554-3563.
15. Komatsu R., Matsuyama T., Namba M., Watanabe N., Itoh H., Kono N., et al. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 1989, 38:902-905.
16. Hayes M.R., Skibicka K.P., Grill H.J. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008, 149:4059-4068.
17. Hayes M.R., Bradley L., Grill H.J. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 2009, 150:2654-2659.
18. Williams D.L., Baskin D.G., Schwartz M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55:3387-3393.
19. Holst J.J., Deacon C.F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005, 48:612-615.
20. Ruttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
21. Mojsov S., Heinrich G., Wilson I.B., Ravazzola M., Orci L., Habener J.F. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986, 261:11880-11889.
22. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
23. Martin B., Dotson C.D., Shin Y.K., Ji S., Drucker D.J., Maudsley S., et al. Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann N Y Acad Sci 2009, 1170:98-101.
24. Kieffer T.J., Habener J.F. The glucagon-like peptides. Endocr Rev 1999, 20:876-913.
25. Eissele R., Goke R., Willemer S., Harthus H.P., Vermeer H., Arnold R., et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992, 22:283-291.
26. Shin Y.K., Martin B., Golden E., Dotson C.D., Maudsley S., Kim W., et al. Modulation of taste sensitivity by GLP-1 signaling. J Neurochem 2008, 106:455-463.
27. Kokrashvili Z., Mosinger B., Margolskee R.F. T1r3 and alpha-gustducin in gut regulate secretion of glucagon-like peptide-1. Ann N Y Acad Sci 2009, 1170:91-94.
28. Holst J.J., Bersani M., Johnsen A.H., Kofod H., Hartmann B., Orskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem 1994, 269:18827-18833.
29. Ritter R.C. Gastrointestinal mechanisms of satiation for food. Physiol Behav 2004, 81:249-273.
30. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal GLP-1 plays a physiological role in satiety. Endocrinology 2008.
31. Blonde L., Klein E.J., Han J., Zhang B., Mac S.M., Poon T.H., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
32. Montanya E., Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009, 31:2472-2488.
33. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
34. Vahl T.P., Tauchi M., Durler T.S., Elfers E.E., Fernandes T.M., Bitner R.D., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148:4965-4973.
35. Nakabayashi H., Nishizawa M., Nakagawa A., Takeda R., Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996, 271:E808-E813.
36. Balkan B., Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1449-R1454.
37. Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 2004, 286:R269-R272.
38. Nishizawa M., Nakabayashi H., Uchida K., Nakagawa A., Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 1996, 61:149-154.
39. Moran T.H., Norgren R., Crosby R.J., McHugh P.R. Central and peripheral vagal transport of cholecystokinin binding sites occurs in afferent fibers. Brain Res 1990, 526:95-102.
40. Verdich C., Flint A., Gutzwiller J.P., Naslund E., Beglinger C., Hellstrom P.M., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001, 86:4382-4389.
41. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520.
42. Scott K.A., Moran T.H. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 2007, 293:R983-R987.
43. Gutzwiller J.P., Drewe J., Goke B., Schmidt H., Rohrer B., Lareida J., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999, 276:R1541-R1544.
44. Naslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999, 23:304-311.
45. Freeman J.S. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med 2009, 76(Suppl 5):S12-S19.
46. Reimer M.K., Holst J.J., Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002, 146:717-727.
47. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996, 2:1254-1258.
48. Scrocchi L.A., Drucker D.J. Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice. Endocrinology 1998, 139:3127-3132.
49. Lachey J.L., D'Alessio D.A., Rinaman L., Elmquist J.K., Drucker D.J., Seeley R.J. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology 2005, 146:458-462.
50. Huo L., Grill H.J., Bjorbaek C. Pro-glucoagon-producing neurons in the nucleus of the solitary tract (NTS) are differentially regulated by leptin in mice and rats. Obesity (Nasso program abstract supplement) 2006, 14:A14.
51. Wan S., Coleman F.H., Travagli R.A. Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. Am J Physiol Gastrointest Liver Physiol 2007, 292:G1474-G1482.
52. Nishizawa M., Nakabayashi H., Kawai K., Ito T., Kawakami S., Nakagawa A., et al. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 2000, 80:14-21.
53. Ruttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal Hepatic-Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 (GLP-1) Reduce Spontaneous Meal Size in the Rat via Different Mechanisms. Endocrinology 2008.
54. Bucinskaite V., Tolessa T., Pedersen J., Rydqvist B., Zerihun L., Holst J.J., et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 2009, 21:978-e78.
55. Cottrell G.T., Ferguson A.V. Sensory circumventricular organs: central roles in integrated autonomic regulation. Regul Pept 2004, 117:11-23.
56. Baraboi E.D., Smith P., Ferguson A.V., Richard D. Lesions of Area Postrema and Subfornical Organ Alter Exendin-4-Induced Brain Activation without Preventing the Hypophagic Effect of the Glp-1 Receptor Agonist. Am J Physiol Regul Integr Comp Physiol. 2010.
57. Hayes M.R., Leichner T.M., Bence K.K., Grill H.J. Intracellular mechanisms mediating the intake suppressive effects of hindbrain GLP-1 receptor activation. The Obesity Society 2009 Annual Meeting 2009.
58. Strain G.W., Gagner M., Pomp A., Dakin G., Inabnet W.B., Hsieh J., et al. Comparison of weight loss and body composition changes with four surgical procedures. Surg Obes Relat Dis 2009, 5:582-587.
59. Peterli R., Wolnerhanssen B., Peters T., Devaux N., Kern B., Christoffel-Courtin C., et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009, 250:234-241.
60. Karamanakos S.N., Vagenas K., Kalfarentzos F., Alexandrides T.K. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008, 247:401-407.
61. Sarwer DB, Faulconbridge LF, Steffen KJ, Roerig JL, Mitchell JE. The Management of Mood Disorders with Anti-depressant Medications After Bariatric Surgery. Current Psychiatry (in press).
62. Rubino F., Schauer P.R., Kaplan L.M., Cummings D.E. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 2010, 61:393-411.
63. Buchwald H., Estok R., Fahrbach K., Banel D., Jensen M.D., Pories W.J., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248-256. e5.
64. Sjostrom L., Lindroos A.K., Peltonen M., Torgerson J., Bouchard C., Carlsson B., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693.
65. Stylopoulos N., Hoppin A.G., Kaplan L.M. Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity (Silver Spring) 2009, 17:1839-1847.
66. Zheng H., Shin A.C., Lenard N.R., Townsend R.L., Patterson L.M., Sigalet D.L., et al. Meal patterns, satiety, and food choice in a rat model of Roux-en-Y gastric bypass surgery. Am J Physiol Regul Integr Comp Physiol 2009, 297:R1273-R1282.
67. Korner J., Bessler M., Inabnet W., Taveras C., Holst J.J. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007, 3:597-601.
68. Gershon M.D. The enteric nervous system: a second brain. Hosp Pract (Minneap) 1999, 34:31-32. 5-8, 41-2 passim.
69. Raybould H.E., Cooke H.J., Christofi F.L. Sensory mechanisms: transmitters, modulators and reflexes. Neurogastroenterol Motil 2004, 16(Suppl 1):60-63.
70. Kindel T.L., Yoder S.M., Seeley R.J., D'Alessio D.A., Tso P. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. J Gastrointest Surg 2009, 13:1762-1772.
71. Morinigo R., Lacy A.M., Casamitjana R., Delgado S., Gomis R., Vidal J. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg 2006, 16:1594-1601.
72. Morinigo R., Moize V., Musri M., Lacy A.M., Navarro S., Marin J.L., et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006, 91:1735-1740.
73. Korner J., Inabnet W., Conwell I.M., Taveras C., Daud A., Olivero-Rivera L., et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006, 14:1553-1561.
74. Osaka T., Endo M., Yamakawa M., Inoue S. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 2005, 26:1623-1631.
75. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002, 110:43-52.
76. Barragan J.M., Eng J., Rodriguez R., Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999, 277:E784-E791.
77. Barragan J.M., Rodriguez R.E., Eng J., Blazquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 1996, 67:63-68.
78. Mack C.M., Moore C.X., Jodka C.M., Bhavsar S., Wilson J.K., Hoyt J.A., et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006, 30:1332-1340.
79. Norgren R. Projections from the nucleus of the solitary tract in the rat. Neuroscience 1978, 3:207-218.
80. Norgren R., Leonard C.M. Ascending central gustatory pathways. J Comp Neurol 1973, 150:217-237.
81. Chaudhri O.B., Parkinson J.R., Kuo Y.T., Druce M.R., Herlihy A.H., Bell J.D., et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun 2006, 350:298-306.
82. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27:313-318.
83. Ma X., Bruning J., Ashcroft F.M. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci 2007, 27:7125-7129.
84. Grill H.J., Norgren R. Neurological tests and behavioral deficits in chronic thalamic and chronic decerebrate rats. Brain Res 1978, 143:299-312.
85. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
86. Meeran K., O'Shea D., Edwards C.M., Turton M.D., Heath M.M., Gunn I., et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999, 140:244-250.
87. Hayes M.R., Bradley L., Grill H.J. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 2009, 150(6):2654-2659.
88. Grill H.J., Schwartz M.W., Kaplan J.M., Foxhall J.S., Breininger J., Baskin D.G. Evidence that the caudal brainstem is a target for the inhibitory effect of leptin on food intake. Endocrinology 2002, 143:239-246.
89. Hayes M.R., Covasa M. Gastric distension enhances CCK-induced Fos-like immunoreactivity in the dorsal hindbrain by activating 5-HT3 receptors. Brain Res 2006, 1088:120-130.
90. Huo L., Maeng L., Bjorbaek C., Grill H.J. Leptin and the control of food intake: neurons in the nucleus of the solitary tract are activated by both gastric distension and leptin. Endocrinology 2007, 148:2189-2197.
91. Smith G.P. The direct and indirect controls of meal size. Neurosci Biobehav Rev 1996, 20:41-46.
92. Rinaman L., Card J.P., Schwaber J.S., Miselis R.R. Ultrastructural demonstration of a gastric monosynaptic vagal circuit in the nucleus of the solitary tract in rat. J Neurosci 1989, 9:1985-1996.
93. Grill HJ, Hayes MR. The NTS: A portal for visceral afferent signal processing, energy status assessment, and integrator of their combined effects on food intake. Int J Obes. 2008.
94. Vrang N., Phifer C.B., Corkern M.M., Berthoud H.R. Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. Am J Physiol Regul Integr Comp Physiol 2003, 285:R470-R478.
95. Perfetti R., Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol 2000, 143:717-725.
96. Gomez E., Pritchard C., Herbert T.P. cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells. J Biol Chem 2002, 277:48146-48151.
97. Vossler M.R., Yao H., York R.D., Pan M.G., Rim C.S., Stork P.J. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 1997, 89:73-82.
98. Dugan L.L., Kim J.S., Zhang Y., Bart R.D., Sun Y., Holtzman D.M., et al. Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem 1999, 274:25842-25848.
99. Hurley R.L., Barre L.K., Wood S.D., Anderson K.A., Kemp B.E., Means A.R., et al. Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem 2006, 281:36662-36672.
100. Xue B., Kahn B.B. AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol 2006, 574:73-83.
101. Minokoshi Y., Alquier T., Furukawa N., Kim Y.B., Lee A., Xue B., et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004, 428:569-574.
102. Seo S., Ju S., Chung H., Lee D., Park S. Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J 2008, 55:867-874.
103. da Silva Xavier G., Leclerc I., Varadi A., Tsuboi T., Moule S.K., Rutter G.A. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J 2003, 371:761-774.
104. Kim M.S., Lee K.U. Role of hypothalamic 5'-AMP-activated protein kinase in the regulation of food intake and energy homeostasis. J Mol Med 2005, 83:514-520.
105. Kim M.S., Park J.Y., Namkoong C., Jang P.G., Ryu J.W., Song H.S., et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004, 10:727-733.
106. Han S.M., Namkoong C., Jang P.G., Park I.S., Hong S.W., Katakami H., et al. Hypothalamic AMP-activated protein kinase mediates counter-regulatory responses to hypoglycaemia in rats. Diabetologia 2005, 48:2170-2178.
107. Hayes MR, Skibicka KP, Bence KK, Grill HJ Dorsal hindbrain AMP-Kinase as an intracellular mediator of energy balance. Endocrinology 2008.
108. Cota D., Proulx K., Smith K.A., Kozma S.C., Thomas G., Woods S.C., et al. Hypothalamic mTOR signaling regulates food intake. Science 2006, 312:927-930.
109. Kim S.J., Nian C., Widenmaier S., McIntosh C.H. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol 2008, 28:1644-1656.
110. Sutton G.M., Duos B., Patterson L.M., Berthoud H.R. Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through extracellular signal-regulated kinase signaling in rat solitary nucleus. Endocrinology 2005, 146:3739-3747.
111. Grill H.J., Hayes M.R. The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake. Int J Obes (Lond) 2009, 33(Suppl 1):S11-S15.
112. Grill H.J. Leptin and the systems neuroscience of meal size control. Front Neuroendocrinol 2010, 31:61-78.
113. Berthoud H.R. Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 2002, 26:393-428.
114. Berthoud H.R., Morrison C. The brain, appetite, and obesity. Annu Rev Psychol 2008, 59:55-92.
115. Myers M.G., Munzberg H., Leinninger G.M., Leshan R.L. The geometry of leptin action in the brain: more complicated than a simple ARC. Cell Metab 2009, 9:117-123.
116. DiLeone R.J. Leptin taking the path less traveled. Cell Metab 2009, 10:77-78.
117. Moran T.H. Gut peptide signaling in the controls of food intake. Obesity (Silver Spring) 2006, 14(Suppl 5):250S-253S.
118. Bartness T.J., Song C.K. Brain-adipose tissue neural crosstalk. Physiol Behav 2007, 91:343-351.
119. Talsania T., Anini Y., Siu S., Drucker D.J., Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005, 146:3748-3756.
120. Neary N.M., Small C.J., Druce M.R., Park A.J., Ellis S.M., Semjonous N.M., et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005, 146:5120-5127.
121. Goldstone A.P., Mercer J.G., Gunn I., Moar K.M., Edwards C.M., Rossi M., et al. Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents. FEBS Lett 1997, 415:134-138.
122. Goldstone A.P., Morgan I., Mercer J.G., Morgan D.G., Moar K.M., Ghatei M.A., et al. Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. Biochem Biophys Res Commun 2000, 269:331-335.
123. Bojanowska E., Nowak A. Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat. J Physiol Pharmacol 2007, 58:349-360.
124. Matson C.A., Reid D.F., Cannon T.A., Ritter R.C. Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 2000, 278:R882-R890.
125. Matson C.A., Wiater M.F., Kuijper J.L., Weigle D.S. Synergy between leptin and cholecystokinin (CCK) to control daily caloric intake. Peptides 1997, 18:1275-1278.
126. Morton G.J., Blevins J.E., Williams D.L., Niswender K.D., Gelling R.W., Rhodes C.J., et al. Leptin action in the forebrain regulates the hindbrain response to satiety signals. J Clin Invest 2005, 115:703-710.
127. Hayes M.R., Skibicka K.P., Leichner T.M., Guarnieri D.J., DiLeone R.J., Bence K.K., et al. Endogenous leptin signaling in the caudal nucleus tractus solitarius and area postrema is required for energy balance regulation. Cell Metab 2010, 11:77-83.